Precision Risk Reduction in ASCVD: Targeting LDL-C, Lp(a), and Inflammation

Precision Risk Reduction in ASCVD: Targeting LDL-C, Lp(a), and Inflammation

STATEMENT OF NEED Cardiovascular disease remains the leading cause of mortality in the US, claiming a life every 34 seconds. Despite effective therapies for atherosclerotic cardiovascular disease (ASCVD), 25.5% of US adults have high low-density lipoprotein cholesterol (LDL-C) with up to 45% of…

Price
Free
Accredited provider:
i3 Health
Learning platform:
IQ Apparatus
Release date
November 19, 2026
Expires
November 19, 2027
Start activity

Credits

Learning objectives

Upon completion, participants should be able to:

  1. Describe the roles of elevated LDL-C, Lp(a), and inflammation in ASCVD and how these risks are addressed by current and emerging therapies
  2. Implement evidence-based screening to identify residual risk in patients with ASCVD
  3. Apply guideline recommendations and clinical data to the design of individualized, multifactorial care plans for patients with ASCVD
  4. Integrate patient-centered, interdisciplinary strategies to optimize ASCVD treatment implementation and adherence

Faculty